Hereditary Angioedema (HAE) Clinical Trial
Official title:
HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
Verified date | May 2021 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Status | Completed |
Enrollment | 125 |
Est. completion date | April 13, 2017 |
Est. primary completion date | April 13, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Males and females 12 years of age or older at time of screening - Documented diagnosis of HAE, Type I or II - Baseline rate of at least 1 Investigator-confirmed HAE attack per 4 weeks - Adult subjects and caregivers of subjects under the age of 18 are willing and able to read, understand, and sign an informed consent form. Subjects age 12 to 17, whose caregiver provides informed consent, are willing and able to read, understand an dsign an assent form. - Males and femailes who are fertile and sexually active must adhere to contraception requirements. Exclusion Criteria: - Concomitant diagnosis of another form of chronic, recurrent angioedema, such as acquired angioedema, idiopathic angioedema, or recurrent angioedema associated with urticaria. - Participation in a prior DX-2930 study - Treatment with any other investigational drug or exposure to an investigational device within 4 weeks prior screening - Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications within 4 weeks prior to screening. - Exposure to androgens within 2 weeks prior to entering the run-in period. - Use of long-term prophylactic therapy for HAE within 2 weeks prior to entering the run-in period. - Use of short-term prophylaxis for HAE within 7 days prior to entering the run-in period. - Any of the following liver function test abnormalities: alanine aminotransferase (ALT) > 3x upper limit of normal, or aspartate aminotransferase (AST) > 3x upper limit of normal, or total bilirubin > 2x upper limit of normal (unless the bilirubin elevation is a result of Gilbert's syndrome). - Pregnancy or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Allergy Research Corporation | Ottawa | Ontario |
Canada | Clinique Specialisee en Allergie de la Capitale | Quebec City | Quebec |
Canada | Gordon Sussman Clinical Research Inc. | Toronto | Ontario |
Germany | Charité - University of Berlin | Berlin | |
Germany | Hautklinik und Poliklinik der Universitätsmedizin | Mainz | |
Germany | HZRM Hamophilie-Zentrum Rhein Main | Morfelden-Walldorf | |
Italy | Hospital L. Sacco, Milan University | Milan | |
Jordan | Triumpharma | Amman | |
Puerto Rico | Sociedad Alergologica | San Juan | |
United Kingdom | Barts Health NHS Trust Clinical Research Centre | London | |
United States | University of Michigan Hospital and Health System | Ann Arbor | Michigan |
United States | Austin Regional Clinic | Austin | Texas |
United States | Hudson-Essex Allergy, LLC | Belleville | New Jersey |
United States | Clinical Research Center of Alabama, LLC | Birmingham | Alabama |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | IMMUNOe International Health & Research Centers | Centennial | Colorado |
United States | American Health Research | Charlotte | North Carolina |
United States | Institute of Asthma & Allergy, P.C. | Chevy Chase | Maryland |
United States | Bernstein Clinical Research Center, LLC | Cincinnati | Ohio |
United States | Asthma and Allergy Associates, P.C. | Colorado Springs | Colorado |
United States | Optimed Research, LTD | Columbus | Ohio |
United States | AARA Research Center | Dallas | Texas |
United States | Intermountain Clinical Research | Draper | Utah |
United States | Duke Asthma, Allergy and Airway Center | Durham | North Carolina |
United States | Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | Children's Hospital of Wisconsin | Milwaukee | Wisconsin |
United States | Winthrop University Hospital | Mineola | New York |
United States | Allergy Associates of Utah | Murray | Utah |
United States | The Mount Sinai Medical Center | New York | New York |
United States | Atlantic Research Center, LLC | Ocean City | New Jersey |
United States | Midwest Immunology Clinic | Plymouth | Minnesota |
United States | Virginia Commonwealth University | Richmond | Virginia |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | UC San Diego School of Medicine | San Diego | California |
United States | AIRE Medical of Los Angeles | Santa Monica | California |
United States | Medical Research of Arizona | Scottsdale | Arizona |
United States | Marycliff Allergy Specialists | Spokane | Washington |
United States | University of South Florida | Tampa | Florida |
United States | Toledo Institute of Clinical Research | Toledo | Ohio |
United States | Allergy & Asthma Clinical Research | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
Shire | Dyax Corp. |
United States, Canada, Germany, Italy, Jordan, Puerto Rico, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks During Treatment Period | HAE attack was defined as a discrete episode during which the participant progressed from no angioedema to symptoms of angioedema. Rate of investigator confirmed HAE attacks was analyzed using a generalized linear model (GLM) for count data assuming a poisson distribution with a log link function and Pearson chi-square scaling of standard errors to account for potential overdispersion. The logarithm of time in days each subject was observed during the treatment period was used as an offset variable in the model. | From Day 0 to Day 182 | |
Secondary | Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attack Requiring Acute Treatment | HAE attack was defined as a discrete episode during which the participant progressed from no angioedema to symptoms of angioedema. Rate of investigator confirmed HAE attack was analyzed using the GLM for count data assuming a poisson distribution with a log link function and Pearson chi-square scaling of standard errors to account for potential overdispersion. The logarithm of time in days each subject was observed during the treatment period was used as an offset variable in the model. | From Day 0 to Day 182 | |
Secondary | Rate of Moderate or Severe Investigator Confirmed Hereditary Angioedema (HAE) Attacks | HAE attack was defined as a discrete episode during which the participant progressed from no angioedema to symptoms of angioedema. Moderate and severe investigator-confirmed HAE attacks were the attacks that were moderate or severe as per the HAE attack assessment and reporting procedures (HAARP) defined severity. The overall severity of attack was determined by the investigator using following definitions: mild (transient or mild discomfort), moderate (mild to moderate limitation in activity), severe (marked limitation in activity). Rate of moderate or severe investigator confirmed HAE attack was analyzed using the GLM for count data assuming a poisson distribution with a log link function and Pearson chi-square scaling of standard errors to account for potential overdispersion. The logarithm of time in days each subject was observed during the treatment period was used as an offset variable in the model. | From Day 0 to Day 182 | |
Secondary | Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks During Day 14 Through Day 182 | HAE attack was defined as a discrete episode during which the participant progressed from no angioedema to symptoms of angioedema. Rate of investigator confirmed HAE attacks during day 14 after study drug administration through day 182 was analyzed by the same poisson regression model as in the primary endpoint analysis. | From Day 14 to Day 182 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02865720 -
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
|
Phase 3 | |
Completed |
NCT04861090 -
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
|
||
Recruiting |
NCT05489640 -
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
|
||
Completed |
NCT02584959 -
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
|
Phase 3 | |
Completed |
NCT01826916 -
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
|
Phase 2 | |
Completed |
NCT04057131 -
FIRAZYR General Drug Use-Results Survey (Japan)
|
||
Recruiting |
NCT05819775 -
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
|
Phase 3 | |
Recruiting |
NCT05397431 -
A Survey of Lanadelumab in Participants With Hereditary Angioedema
|
||
Completed |
NCT02741596 -
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
|
Phase 3 | |
Completed |
NCT02093923 -
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
|
Phase 1 | |
Completed |
NCT01541423 -
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
|
||
Completed |
NCT03845400 -
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
|
||
Completed |
NCT02052141 -
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
|
Phase 3 | |
Completed |
NCT03888755 -
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
|
Phase 3 | |
Recruiting |
NCT05147181 -
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
|
||
Recruiting |
NCT05469789 -
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
|
||
Completed |
NCT05460325 -
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
|
Phase 3 | |
Completed |
NCT01095510 -
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
|
Phase 2 | |
Recruiting |
NCT05578417 -
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
|
||
Withdrawn |
NCT01253382 -
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
|
Phase 2/Phase 3 |